Phase 2
Completed N=341
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Pancreatic Adenocarcinoma
Source: ClinicalTrials.gov NCT03193190 ↗
Enrolled (actual)
341
Serious AEs
45.2%
Results posted
Nov 2025
Primary outcomePrimary: Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 37.5; 55.6; 48.0; 26.7 percentage of participants
Summary
A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).
Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) |
37.5; 55.6; 48.0; 26.7; 31.7; 30.0 | — |
| SECONDARY Number of Participants With Adverse Events (AEs) |
32; 9; 24; 15; 41; 30 | — |
| SECONDARY Stage 1: Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1 |
6.11; 4.04; 7.18; 8.21; 5.82; 5.39 | — |
| SECONDARY Stage 1: Overall Survival (OS), as Determined by Investigator According to RECIST v1.1 |
14.55; 9.03; 13.34; 16.49; 13.34; 11.20 | — |
| SECONDARY Stage 1: OS Rate at Month 6 |
87.07; 55.56; 83.48; 80.00; 72.55; 86.67 | — |
| SECONDARY Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST v1.1 |
5.40; 3.35; 8.18; 4.85; 4.47; 5.65 | — |
| SECONDARY Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST v1.1 |
81.3; 55.6; 64.0; 66.7; 61.0; 66.7 | — |
Eligibility Criteria
Inclusion Criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma
- For patients in Cohort 1: no prior systemic treatment for PDAC
- For patients in Cohort 2: disease progression during administration of either 5-FU- or gemcitabine-based first-line chemotherapy
- Life expectancy greater than or equal to 3 months
- Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing
- Measurable disease (at least one target lesion) according to RECIST v1.1
- Adequate hematologic and end-organ function test results
- Tumor accessible for biopsy
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as outlined for each specific treatment arm
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm
Exclusion Criteria
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage procedure (i.e., more than one time per month)
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- History of leptomeningeal disease
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Positive human immunodeficiency (HIV) test at screening or at any time prior to screening
- Active hepatitis B or C virus infection or active tuberculosis
- Severe infection within 4 weeks prior to initiation of study treatment
- Prior allogeneic stem cell or solid organ transplantation
- History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
Data sourced from ClinicalTrials.gov (NCT03193190). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.